Posts Tagged acute myeloid leukemia
-
Coronado Biosciences to Moderate Diabetes Panel at the 8th Annual Swedish-American Life Science Summit in Stockholm
BURLINGTON, Mass., Aug. 22, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that Dr. Karin Hehenberger, Executive Vi...
-
Cyclacel Pharmaceuticals to Announce Release of Second Quarter 2012 Financial Results
BERKELEY HEIGHTS, N.J., Aug. 10, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious di...
-
DACOGEN(R) Receives a Positive Regulatory Recommendation in the European Union for Treatment of Acute Myeloid Leukemia
DUBLIN, Calif., July 20, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that Janssen-Cilag International NV was notified that the Committee for Medical Produ...
-
Cyclacel to Announce Year-End and Fourth Quarter 2011 Financial Results and Multiple Presentations at the Upcoming AACR Conference
BERKELEY HEIGHTS, N.J., March 26, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") today announced upcoming corporate events. Year End and Fourth Quarter 2011 Financial Results – Thursday, March 29, 2012 Cyclacel will announce yea...
-
Coronado Biosciences to Host Analyst & Investor Event in New York City
BURLINGTON, Mass., March 13, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, will be hosting an analyst and investor event on Friday, March 30...
-
Cyclacel Announces Abstracts Selected for Presentation at American Association for Cancer Research Annual Meeting
BERKELEY HEIGHTS, N.J., March 29, 2011 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), announced today that two abstracts highlighting preclinical data for Cyclacel's cell cycle inhibitor drugs have been selected for presentation at the Amer...
-
Cyclacel’s Second Generation Cyclin-Dependent Inhibitor CYC065 Demonstrates Activity in Multiple Myeloma
BERKELEY HEIGHTS, N.J., Dec. 5, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious...
-
Cyclacel Reports Phase 2 Survival Data With Sapacitabine in Myelodysplastic Syndromes at 2010 ASH Annual Meeting
BERKELEY HEIGHTS, N.J., Dec. 4, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel") announced today 1-year survival data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic sy...
